Navigation Links
First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System
Date:3/17/2008

WILMINGTON, Mass., March 17 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices for use in the treatment of vascular disease, announced today that it has enrolled its first patient in the SONIC I Clinical Registry. SONIC I is a prospective, multi-centered U.S. registry study of the company's OmniWave(TM) Endovascular System (OES) in patients undergoing percutaneous mechanical thrombectomy of acute deep vein thrombosis (DVT). All patients enrolled in the SONIC I are scheduled for follow-up at 30 days and 6 months following the OmniWave procedure. The first patient was enrolled by Daniel Clair, M.D., Chairman of Vascular Surgery at The Cleveland Clinic.

"The Cleveland Clinic is excited to participate in the SONIC I clinical trial with the OmniWave Endovascular System," said Dr. Clair. "The OmniWave System has the potential to offer physicians an effective alternative to current pharmacological and mechanical treatments for deep vein thrombosis (DVT)."

In response to this important milestone, Richard Ganz, President and CEO of OmniSonics Medical Technologies, said, "We continue to be encouraged by the positive outcomes the first physicians are having with the OmniWave Endovascular System. Enrolling our first patient in the SONIC I Clinical Registry is a key step in our contribution to providing tools to physicians for the treatment of DVT."

In September 2007, OmniSonics received clearance from the Food and Drug Administration (FDA) to market its catheter-based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature.

OmniSonics Medical Technologies, Inc. is scheduled to exhibit the OmniWave Endovascular System at the Society for Interventional Radiology (SIR) Meeting to be held March 15-20 in Washington, DC.

The OmniWave Endovascular System is based on patented OmniWave technology
'/>"/>

SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
6. First-Ever Cancer and Careers Seminar Debuts in Orange County
7. Pharmaxis First Steps into China
8. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
9. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
10. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
11. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
(Date:12/10/2009)... ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and ... at various stages of development, today provided an ... in the merger of Cytopia Ltd. into YM, ... 2009. The board of directors of Cytopia has ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4
... the Board -, MADISON, N.J., April 24 ... Robert Essner, 60, has decided to retire,from the Company ... position,of Chairman since January 2003 and served as Wyeth,s ... of Directors has elected,Bernard Poussot, Wyeth,s President and Chief ...
... N.J., April 24 Pharmasset, Inc.,(Nasdaq: VRUS ) ... Conference being held from April 30, 2008 to May ... Schaefer Price,Pharmasset,s Chief Executive Officer, will provide an overview ... Morgan Stanley,representatives on Wednesday, April 30, 2008 at 3:40 ...
... genetics,Inc. (Nasdaq: DCGN ) today announced that it will ... to be issued on Thursday, May 1,after the close of ... live,webcast of its conference call to discuss these results and ... noon GMT/1pm,British Summer Time., The webcast can be accessed ...
Other Biology Technology:Wyeth Chairman Robert Essner Announces June 27 Retirement 2Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th 2deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results 2
(Date:12/13/2009)... discovered five genetic variants that are associated with the ... international consortium of 96 scientists from 63 centres in ... basis of lung diseases. , The new findings provide ... Obstructive Pulmonary Disease (COPD) and asthma. In the past ... the molecular pathways that affect the health of the ...
(Date:12/11/2009)... COLLINS, COWild Malus orientalis species of wild apples ... native to the Middle East and Central Asia. A ... M. orientalis varieties from Georgia and Armenia with ... the large population and establishes a core collection that ... the breeding and research communities. , To identify and ...
(Date:12/11/2009)... CLEVELAND Case Western Reserve University has granted ... Inc. regarding a portfolio of insulin analogs. The ... exercise its option to obtain an exclusive license ... , Cleveland-based Thermalin Diabetes is developing treatments that ... the $12 billion, rapidly growing insulin market. Insulin ...
Breaking Biology News(10 mins):New genes for lung disease discovered 2Understanding apples' ancestors 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Neural stem cell differentiation factor discovered 9064 1Neural stem cell differentiation factor discovered 9064 2First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 1First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 2First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 3First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 4Allegiant Professional Business Services Inc Signs New Members to Its PPO Health Insurance Plan Annual Revenues Projected to Increase by 245M 50391 1Allegiant Professional Business Services Inc Signs New Members to Its PPO Health Insurance Plan Annual Revenues Projected to Increase by 245M 50391 2
... The American Dietetic Association has released an updated ... enhanced foods can benefit a person,s health when consumed ... and urges continued efforts to educate the public on ... issue of the Journal of the American Dietetic ...
... MD, PhD is the inaugural recipient of the Richard King ... American College of Medical Genetics Foundation (ACMGF) to encourage ABMG ... quality research in Genetics in Medicine. Each year the editorial ... ABMG trainee who was either a first or corresponding author ...
... H. Holmes Pioneer Awards will be presented on April 3 ... The awards honor two recipients who have contributed to the ... will be presented to Lawrence Platt, MD, of the David ... Los Angeles, California. The basic science award will be presented ...
Other Biology News:ADA releases updated position statement on functional foods 2ADA releases updated position statement on functional foods 3Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2AIUM Presents 2009 Joseph H. Holmes Pioneer Awards 2
...
BD Falcon microtest assay plate. 1536 well 12l, black BD Optilux PS. Polystyrene, nonsterile, no lid (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... low background fluorescence, minimal light scatter ... medium binding) polystyrene surface is hydrophobic ... passive interactions,• Is suitable primarily ... such as antibodies, that have large ...
... Sulfo SBED Protein:Protein Interaction Reagent A ... has rapidly gained traction as an in ... growing number of publications feature the exclusive ... to study a variety of issues relating ...
Biology Products: